Earnings History Data for BioMarin Pharmaceutical Inc. (BMRN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
29-10-2024	AH		BMRN	BioMarin Pharmaceutical Inc.	13,280	0.74	0.57	0.26	BioMarin Pharmaceutical Non-GAAP EPS of $0.91 beats by $0.12, revenue of $745.74M beats by $42.43M [10/29/2024 4:04 PM]	66.83	-3.08 (-4.41%)	68.01	-1.90 (-2.72%)	65.78 - 99.56	2,369,469	1,380,000	14,475
BioMarin Pharmaceutical Non-GAAP EPS of $0.91 beats by $0.12, revenue of $745.74M beats by $42.43M [10/29/2024 4:04 PM] BioMarin downgraded at William Blair following narrowing of revenue guidance [10/30/2024 1:05 PM] BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook [2024-10-29 04:03PM] BioMarin: Q3 Earnings Snapshot [2024-10-29 04:20PM] BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates [2024-10-29 05:20PM]
05-08-2024	AH		BMRN	BioMarin Pharmaceutical Inc.	16,070	0.77	0.38	0.34	BioMarin Pharmaceutical Non-GAAP EPS of $0.96 beats by $0.36, revenue of $712.03M beats by $49.76M [8/5/2024 4:05 PM]	86.94	6.47 (8.04%)	85.60	5.13 (6.38%)	73.68 - 99.56	3,230,830	1,230,000	1,296
BioMarin Pharmaceutical Non-GAAP EPS of $0.96 beats by $0.36, revenue of $712.03M beats by $49.76M [8/5/2024 4:05 PM] BioMarin raises 2024 guidance for revenue, non-GAAP EPS [8/5/2024 5:13 PM] BioMarin to focus Roctavian efforts on US, Germany, Italy [8/5/2024 5:37 PM]
24-04-2024	AH		BMRN	BioMarin Pharmaceutical Inc.	16,880	0.49	0.37	0.39	BioMarin Pharmaceutical Non-GAAP EPS of $0.71 beats by $0.11, revenue of $648.83M misses by $2.98M [4/24/2024 4:03 PM]	81.83	-9.38 (-10.28%)	86.52	-4.68 (-5.13%)	76.02 - 99.56	7,504,188	1,610,000	18,472
BioMarin updated 2024 guidance sees EPS raise, but no change to revenue [4/24/2024 5:22 PM] BioMarin Pharmaceutical Non-GAAP EPS of $0.71 beats by $0.11, revenue of $648.83M misses by $2.98M [4/24/2024 4:03 PM]
22-02-2024	AH		BMRN	BioMarin Pharmaceutical Inc.	16,720	0.26	0.24	0.11	BioMarin Pharmaceutical Non-GAAP EPS of $0.49 beats by $0.04, revenue of $646.2M beats by $8.63M [2/22/2024 4:07 PM]	91.20	1.23 (1.37%)	92.39	2.42 (2.69%)	76.02 - 103.97	2,262,561	1,380,000	41,773
BioMarin Pharmaceutical Non-GAAP EPS of $0.49 beats by $0.04, revenue of $646.2M beats by $8.63M [2/22/2024 4:07 PM]
01-11-2023	AH		BMRN	BioMarin Pharmaceutical Inc.	15,240	0.26	0.28	0.16	BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02, revenue of $581.3M misses by $26.46M [11/1/2023 4:29 PM]	79.63	-4.38 (-5.21%)	80.01	-4.00 (-4.76%)	76.02 - 117.77	4,122,316	1,240,000	40,013
BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02, revenue of $581.3M misses by $26.46M [11/1/2023 4:29 PM] BioMarin appoints Alexander Hardy as president and chief executive officer [11/1/2023 4:27 PM] BioMarin Pharmaceutical says CEO Bienaimé to retire, Hardy to take up post [11/2/2023 11:08 AM]
31-07-2023	AH		BMRN	BioMarin Pharmaceutical Inc.	16,250	0.34	0.24	0.33	BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line [7/31/2023 4:06 PM]	88.98	1.05 (1.19%)	87.00	-0.93 (-1.06%)	80.53 - 117.77	2,922,784	1,080,000	1,189
BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line [7/31/2023 4:06 PM]
26-04-2023	AH	4:00 PM ET (Apr 26)	BMRN	BioMarin Pharmaceutical Inc.	18,040	0.39	0.24	0.31	BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M [4/26/2023 4:06 PM]	92.42	-0.58 (-0.62%)	93.00	0.0 (0.00%)	70.73 - 117.77	1,760,120	1,130,000	45,147
BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M [4/26/2023 4:06 PM]
27-02-2023	AH	4:00 PM ET (Feb 27)	BMRN	BioMarin Pharmaceutical Inc.	19,160	0.11	0.12	-0.21	BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M [2/27/2023 4:06 PM]	99.62	-3.62 (-3.51%)	99.40	-3.84 (-3.72%)	70.73 - 117.77	2,262,166	1,230,000	3,640
BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M [2/27/2023 4:06 PM]
26-10-2022	AH	4:00 PM ET (Oct 26)	BMRN	BioMarin Pharmaceutical Inc.	16,670	0.16	0.12	-0.03	BioMarin Pharmaceutical GAAP EPS of -$0.04 misses by $0.03, revenue of $505.3M misses by $10.56M [10/26/2022 4:06 PM]	85.69	-6.40 (-6.95%)	89.00	-3.10 (-3.37%)	70.73 - 97.76	3,790,127	1,320,000	1,129
BioMarin Pharmaceutical GAAP EPS of -$0.04 misses by $0.03, revenue of $505.3M misses by $10.56M [10/26/2022 4:06 PM] BioMarin GAAP net loss narrows 82% in Q3, but not enough to beat on bottom line [10/26/2022 5:40 PM] BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®) [Oct-26-22 04:03PM]
03-08-2022	AH	4:00 PM ET (Aug 3)	BMRN	BioMarin Pharmaceutical Inc.	15,770	0.33	0.20	0.23	BioMarin Pharmaceutical GAAP EPS of $0.15 beats by $0.06, revenue of $533.8M beats by $11.87M, raises FY22 revenue guidance [8/3/2022 4:15 PM]	92.97	4.57 (5.17%)	3.92	-0.40 (-9.26%)	70.73 - 94.20	2,227,560	860,000	51,552
BioMarin Pharmaceutical GAAP EPS of $0.15 beats by $0.06, revenue of $533.8M beats by $11.87M, raises FY22 revenue guidance [8/3/2022 4:15 PM] BioMarin boosts 2022 top and bottom line guidance on back of product sales growth [8/3/2022 4:55 PM] BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance [Aug-03-22 04:03PM]
27-04-2022	AH	4:00 PM ET (Apr 27)	BMRN	BioMarin Pharmaceutical Inc.	15,140	0.31	0.15	0.29	BioMarin Pharmaceutical GAAP EPS of $0.63 beats by $0.39, revenue of $519M beats by $9.69M [4/27/2022 4:04 PM]	82.88	2.57 (3.20%)	83.50	3.19 (3.97%)	71.59 - 94.20	1,947,295	970,000	8,696
BioMarin Pharmaceutical GAAP EPS of $0.63 beats by $0.39, revenue of $519M beats by $9.69M [4/27/2022 4:04 PM] Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More [Apr-26-22 11:44AM] BioMarin Announces Record Revenues in First Quarter 2022 [Apr-27-22 04:02PM] BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates [Apr-27-22 05:25PM] Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y [Apr-28-22 12:30PM] BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates [Apr-28-22 02:35PM]
23-02-2022	AH	4:05 PM ET (Feb 23)	BMRN	BioMarin Pharmaceutical Inc.	15,580	-0.21	-0.13	-0.05	BioMarin Pharmaceutical GAAP EPS of -$0.32 beats by $0.02, revenue of $449.8M beats by $7.42M [2/23/2022 4:12 PM]	77.25	-5.27 (-6.39%)	79.00	-3.52 (-4.27%)	71.59 - 94.20	3,859,606	1,246,703	56,904
BioMarin Pharmaceutical GAAP EPS of -$0.32 beats by $0.02, revenue of $449.8M beats by $7.42M [2/23/2022 4:12 PM] Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More [Feb-22-22 12:01PM] BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates [Feb-23-22 04:03PM] BioMarin Pharmaceutical (BMRN) Q4 Earnings and Revenues Top Estimates [Feb-23-22 05:25PM] BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y [Feb-24-22 10:50AM] Why BioMarin Pharmaceutical Tumbled on Thursday [Feb-24-22 05:09PM]
27-10-2021	AH	4:00 PM ET (Oct 27)	BMRN	BioMarin Pharmaceutical Inc.	13,520	-0.03	-0.12	0.29	BioMarin Pharmaceutical EPS beats by $0.06, misses on revenue [10/27/2021 4:18 PM]	78.13	6.41 (8.94%)	73.09	1.37 (1.91%)	71.59 - 92.56	4,531,761	1,390,000	715
BioMarin Pharmaceutical EPS beats by $0.06, misses on revenue [10/27/2021 4:18 PM] BioMarin tightens 2021 guidance after mixed performance in Q3 [10/27/2021 5:01 PM] LAWSUITS FILED AGAINST EAR, BMRN and RECAF -Jakubowitz Law Pursues Shareholders Claims [Oct-26-21 08:35PM] BMRN DEADLINE: BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit [Oct-26-21 08:04PM] SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - BMRN [Oct-26-21 05:26PM] SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Oct-26-21 03:50PM] ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BMRN [Oct-26-21 03:39PM] CLASS ACTION UPDATE for HYRE, WDH and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [Oct-26-21 01:40PM] BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit [Oct-26-21 12:38PM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPLT, BMRN and AMRN [Oct-26-21 10:45AM] BMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: December 21, 2021 [Oct-26-21 10:00AM] SHAREHOLDER ALERT: HEPS BMRN AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines [Oct-26-21 05:40AM] 10 Healthcare and Software Stocks to Buy According to Michel Massouds Melqart Asset Management [Oct-27-21 07:25AM] SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Oct-27-21 09:06AM] CLASS ACTION UPDATE for EAR, NNOX and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [Oct-27-21 09:35AM] BMRN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: December 21, 2021 [Oct-27-21 11:00AM] SHAREHOLDER ALERT: INNV HEPS BMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines [Oct-27-21 11:45AM] BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates [Oct-27-21 04:05PM] BIOMARIN PHARMACEUTICAL INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioMarin Pharmaceutical Inc. [Oct-27-21 05:31PM] Lawsuits Filed Against SAM, BMRN and RECAF - Jakubowitz Law Pursues Shareholders Claims [Oct-27-21 06:50PM] BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates [Oct-27-21 05:35PM] BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm [Oct-27-21 09:00PM] BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transcript [Oct-28-21 12:01AM] BMRN ALERT: Robbins Geller Rudman & Dowd LLP Announces that BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit [Oct-27-21 11:08PM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZEV, BMRN and AMRN [Oct-28-21 05:40AM] BioMarin Pharmaceutical Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioMarin Pharmaceutical Inc. [Oct-28-21 08:32AM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HYZN, BMRN and AMRN [Oct-28-21 09:20AM] BioMarin's Q3 Net Income Hit By Lower Product Sales [Oct-28-21 07:14AM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HYZN, INNV and BMRN [Oct-28-21 10:30AM] SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Oct-28-21 01:10PM] BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance [Oct-28-21 11:43AM] ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action BMRN [Oct-28-21 06:52PM] BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 22, 2021 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders [Oct-28-21 05:25PM] BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. [Oct-28-21 03:45PM]
28-07-2021	AH	4:00 PM ET (Jul 28)	BMRN	BioMarin Pharmaceutical Inc.	14,140	0.23	0.05	0.07	BioMarin Pharmaceutical EPS beats by $0.18, beats on revenue [7/28/2021 4:10 PM]	78.53	-0.20 (-0.25%)	79.55	0.82 (1.04%)	71.35 - 124.52	966,048	980,000	3,102
BioMarin Pharmaceutical EPS beats by $0.18, beats on revenue [7/28/2021 4:10 PM] BioMarin shares rise on Q2 earnings beat, FY topline forecast raise [7/28/2021 4:45 PM] Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY [Jul-27-21 11:14AM] Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View [Jul-28-21 10:00AM] BioMarin (BMRN) Upgraded to Strong Buy: Here's What You Should Know [Jul-28-21 12:00PM] BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates [Jul-28-21 04:03PM] BioMarin Bounces Back [Jul-28-21 07:14PM] BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates [Jul-28-21 06:15PM] BioMarin Stock Bounces Back With Solid Earnings [Jul-28-21 08:19PM] BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript [Jul-29-21 03:32AM] BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance [Jul-29-21 02:17PM]
29-04-2021	AH	4:05 PM ET (Apr 29)	BMRN	BioMarin Pharmaceutical Inc.	14,820	0.29	0.07	0.38	BioMarin Pharmaceutical EPS beats by $0.19, beats on revenue [4/29/2021 4:10 PM]	77.88	-2.30 (-2.87%)	78.25	-1.93 (-2.41%)	71.35 - 131.94	1,275,871	780,000	5,770
BioMarin Pharmaceutical EPS beats by $0.19, beats on revenue [4/29/2021 4:10 PM] PDUFA date for BioMarin's vosoritide extended by three months [4/29/2021 5:49 PM] Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases [Apr-28-21 08:31AM] BioMarin Pharmaceutical, Inc. to Host Earnings Call [Apr-29-21 02:30PM] BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates [Apr-29-21 04:03PM] BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates [Apr-29-21 05:25PM] Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript [Apr-29-21 11:31PM] BioMarin Reports Better-Than-Expected 1Q Results [Apr-30-21 08:49AM] BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision [Apr-30-21 09:58AM]
25-02-2021	AH	4:05 PM ET (Feb 25)	BMRN	BioMarin Pharmaceutical Inc.	14,910	-0.05	-0.06	0.09	BioMarin Pharmaceutical EPS beats by $0.29, beats on revenue [2/25/2021 4:11 PM]	77.48	-4.28 (-5.23%)	79.00	-2.76 (-3.38%)	68.25 - 131.94	2,353,573	1,121,882	1,535
BioMarin Pharmaceutical EPS beats by $0.29, beats on revenue [2/25/2021 4:11 PM] BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull [Feb-26-21 09:16AM] BioMarin Pharmaceutical, Inc. to Host Earnings Call [Feb-25-21 02:30PM]
05-11-2020	AH	4:05 PM ET (Nov 5)	BMRN	BioMarin Pharmaceutical Inc.	13,170	0.29	-0.01	0.22	BioMarin Pharmaceutical EPS beats by $2.97, beats on revenue [11/5/2020 4:13 PM]	76.73	1.68 (2.24%)	74.44	-0.61 (-0.81%)	68.25 - 131.94	1,854,769	1,503,365	17,514

04-08-2020	AH	4:00 PM ET (Aug 4)	BMRN	BioMarin Pharmaceutical Inc.	21,670	0.07	-0.10	-0.08	BioMarin Pharmaceutical EPS misses by $0.04, beats on revenue, expects FY20 GAAP profit [8/4/2020 4:09 PM]	120.09	0.26 (0.22%)	119.80	-0.03 (-0.02%)	62.88 - 131.94	693,279	970,055	1,546